COVID-19 Research Initiatives at the FNL

Douglas R. Lowy, M.D.
Principal Deputy Director

Fourth Virtual Meeting of the Frederick National Laboratory Advisory Committee (FNLC)

July 13, 2020
Topics for today

• Serology at Frederick National Lab
• Serology network
• Serology dashboard
• COVID-19 natural history in cancer patients
• Cancer prevention & screening
Supplemental funding from Congress

- Enacted April 24th
- $306M for NCI to develop, validate, improve, and implement serological testing and associated technologies
- COVID-19-focused and distinct from annual appropriation
Convert part of HPV serology lab to SARS-CoV-2 serology

A collaborative research effort with several groups: NIAID, FDA, CDC, Mount Sinai, others

**Shorter term goals**
1. Characterize performance of different serologic assays, correlate with neutralization assays, understand possible cross-reacting sera from prior to epidemic;
2. Correlations with serologic tests submitted to FDA

**Longer term goals**
Understand implications of being seropositive (e.g., resistance to reinfection), duration of seropositivity

**Cohort oriented research projects:** COVID-19 longitudinal trial of cancer patients, others
Summary of initial 70 commercial serology devices evaluated by FNLCR serology laboratory

- Focus on IgG antibody tests; IgM becomes positive at about the same time as IgG and decreases faster than IgG
- **Sensitivity** (detect true positives): Varies from 30% to 100%
- **Specificity** (does not detect false-positives): Varies from 87% to 100%
- Results sent to FDA to help FDA determine suitability for Emergency Use Authorization (EUA)
Additional activities at FNL serology lab

• FNL protein expression lab is producing large amounts of SARS-CoV-2 antigens for use in serologic assays, at FNL and NIBIB

• Serology lab is developing quantitative SARS-CoV-2 antibody assays
  • Until now, assay results have been qualitative

• Serology lab is developing a “standard” pooled serum for US govt and beyond; collaboration with NIAID, CDC, BARDA
  • Will eventually be linked to WHO standard serum when it is available
Some SARS-CoV-2 serology questions

• It is not currently known:
  o whether being antibody-positive is associated with protection against reinfection
  o what antibody levels may be associated with protection
  o how long protection will last

• NCI is co-funding extramural research with NIAID and CDC to address these questions

• For candidate SARS-CoV-2 vaccines, will induction of neutralizing antibodies confer protection?
  o The serological standard will enable direct comparisons of immunogenicity between candidate vaccines
Extramural Serological Sciences Network
Serological Sciences Network for COVID-19 (SeroNet)

To rapidly expand understanding of all aspects of the immune response associated with SARS-CoV-2 viral infection.

GOALS

- Increase national capacity for high-quality serological testing
- Develop serological assays for deployment to test for SARS-CoV-2 induced immune responses
- Understand the mechanisms driving the serological, humoral and cellular immune responses
- Determine the serological correlates of disease pathogenesis and protection against future infection
SeroNet “hub and spokes”

4-8 CBCs: Serological Sciences Capacity Building Centers (RFP)

4-8 U54s: Serological Sciences Centers of Excellence (RFA)

5-10 U01s: Serological sciences projects (RFA)
## Serological Sciences Network for COVID-19 (SeroNet)

### Capacity Building Centers (Contracts)
- Develop and expand serological testing capacity
- 4-8 contracts with academic and/or private sector through FNLCR

### Serological Sciences Centers of Excellence (U54)
Each Center:
- 2-3 Research Projects
- Administrative Core
- Optional shared resource core
- 4-8 awards

### Serological Sciences Research Projects (U01)
- Up to $500K direct costs per year, up to 5 years
- 5-10 awards

---

**Network Coordinating Center**

**FNL Serology Lab**
Tracking SARS-CoV-2 seroprevalence and more
Developing a SARS-CoV-2 serology data warehouse and dashboard

- Early June: HHS, CDC, NIAID ask NCI to develop data warehouse & dashboard for tracking SARS-CoV-2 seroprevalence and other US-based serology studies
- Builds on FNL dashboard expertise developed with NCI Clinical Trials Reporting Program (CTRP), other databases
  - Collaboration between NIAID, CDC, NCI
- Key features:
  - A publicly accessible data warehouse to systematically document and track SARS-CoV-2 serology studies and associated test results
  - A tracking dashboard to visualize SARS-CoV-2 serology data and present results overall and by key strata
Vision for Sero-tracker

Infrastructure to hold information and allow user access to dashboard and reports

• Comprehensive view of near real-time COVID-19 status
• Identification of gaps and disparities across demographic factors
• Scientific assessment of study results
• Transparency of government funding

<table>
<thead>
<tr>
<th>Project Identifier</th>
<th>National_Clinical_Trial_Identifier</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study name</td>
<td>Study reference</td>
</tr>
<tr>
<td>Study_Design</td>
<td>Comments</td>
</tr>
<tr>
<td>Study_population</td>
<td>Zip Code</td>
</tr>
<tr>
<td>Study_Keywords</td>
<td>Test specificity</td>
</tr>
<tr>
<td>Sampling strategy</td>
<td>Collection Date</td>
</tr>
<tr>
<td>Collection Country</td>
<td>Gender</td>
</tr>
<tr>
<td>Collection_State</td>
<td>Study Title</td>
</tr>
<tr>
<td>Number_of_Participants</td>
<td>Study Description</td>
</tr>
<tr>
<td>Collection_Period</td>
<td>Study Date</td>
</tr>
<tr>
<td>Subject_Age_Group</td>
<td>Test Manufacturer</td>
</tr>
<tr>
<td>Name and type of test</td>
<td>Assay Metadata</td>
</tr>
<tr>
<td>Test sensitivity</td>
<td>Tested prevalence (Seroprevalence)</td>
</tr>
<tr>
<td>Study Title</td>
<td>Subjects Enrolled</td>
</tr>
<tr>
<td>-------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>NCI COVID-19 in Cancer Patients, NICEAPS Study</td>
<td>2,000</td>
</tr>
<tr>
<td>A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19)</td>
<td>17</td>
</tr>
<tr>
<td>Application of Desferal to Treat COVID-19</td>
<td>50</td>
</tr>
<tr>
<td>A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection</td>
<td>310</td>
</tr>
<tr>
<td>Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression</td>
<td>1,600</td>
</tr>
<tr>
<td>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</td>
<td>42</td>
</tr>
<tr>
<td>Inhaled Nitric Oxide for Preventing Progression in COVID-19</td>
<td>86</td>
</tr>
<tr>
<td>Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19</td>
<td>120</td>
</tr>
<tr>
<td>A Study of Hydroxychloroquine Compared to Placebo as Treatment for People With COVID-19</td>
<td>1,800</td>
</tr>
<tr>
<td>A Study of N-acetylcysteine in Patients with COVID19 Infection</td>
<td>86</td>
</tr>
</tbody>
</table>

Sortable

Dynamic Popups showing any data elements deemed appropriate.
Dynamic popups showing any data elements deemed appropriate.

Clear highlight of seroprevalence

<table>
<thead>
<tr>
<th>Total Number of Studies</th>
<th>20</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Number of Subjects</td>
<td>19,261</td>
</tr>
<tr>
<td>Average Number of Subjects</td>
<td>963</td>
</tr>
<tr>
<td>Average Duration</td>
<td>12 months</td>
</tr>
<tr>
<td>Average Seroprevalence</td>
<td>2.71%</td>
</tr>
</tbody>
</table>
Longitudinal natural history of COVID-19 in people with cancer
NCI COVID-19 in Cancer Patients Study (NCCAPS)

• Enroll a large cohort of patients across all of NCI’s clinical trials networks who are undergoing cancer therapy and who test positive for SARS-CoV-2 to characterize factors associated with COVID-19 severity.

• Describe modifications to cancer treatment made due to COVID-19.

• Evaluate the association of COVID-19 with cancer outcomes in clinico-pathologic subgroups.

• Assess anti-SARS-CoV-2 antibody development, cytokine abnormalities, and genetic polymorphisms associated with severe COVID-19.

• Create a bank of clinical data, research blood specimens, and radiological images for future research.
Informed consent may be done remotely.

Patients are **not** required to have any extra visits for this study.

- Research blood specimens will be collected at the same time blood is drawn as part of regular clinical care.
- Imaging scans collected for banking are those scans being done as part of clinical care.

Research blood tests do **not** require on-site processing.

- Specimen kits will be provided, including shipping to the biorepository.

Sites receive full accrual credit for enrollments to Step 1, partial credit for step 0, per the ETCTN, NCORP, and NCTN guidelines.
COVID-19 epidemic may stimulate modified approaches to cancer screening
Using COVID-19 epidemic to help overcome higher cervical cancer mortality rates in Black women

FDA is willing to consider self-collected vaginal specimens for cervical cancer screening. Could enable screening of “hard to reach” women, which could decrease cervical cancer incidence and mortality.

<table>
<thead>
<tr>
<th>Year of Diagnosis</th>
<th>Black (includes Hispanic)</th>
<th>White (includes Hispanic)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>35.0</td>
<td>20.0</td>
</tr>
<tr>
<td>2010</td>
<td>30.0</td>
<td>15.0</td>
</tr>
<tr>
<td>2005</td>
<td>25.0</td>
<td>10.0</td>
</tr>
<tr>
<td>2000</td>
<td>20.0</td>
<td>5.0</td>
</tr>
<tr>
<td>1995</td>
<td>15.0</td>
<td>0.0</td>
</tr>
</tbody>
</table>

Cervical cancer Incidence

Current mortality rates
ASR* 2012-2016

Black women: 3.5
White women: 2.2

*ASR=Annual Standardized Rate
Thanks to

- Ligia Pinto, Troy Kemp, Jim Cherry: NCI Frederick Serology lab
- Dom Espisito, FNL Protein Expression Lab
- Ned Sharpless, Dinah Singer, Jim Doroshow
- Tony Kerlavage, Stephen Chanock, Neal Freedman, Jonas de Almeda
- Brent Coffey and his FNL team